CD20.BBz CAR-T

CD20.BBz CAR-T is an experimental second-generation chimeric antigen receptor (CAR) T-cell therapy designed to target the CD20 antigen, a protein widely expressed on the surface of normal and malignant B cells. The construct incorporates an anti-CD20 single-chain variable fragment (scFv) for antigen recognition, a 4-1BB (CD137) costimulatory domain to enhance T-cell metabolic fitness and persistence, and a CD3ζ signaling domain to initiate T-cell activation upon binding. This specific CAR-T construct has been utilized in advanced non-human primate (NHP) models to investigate the genetic drivers of CAR-T expansion, tissue infiltration, and long-term persistence. Researchers from institutions including the Dana-Farber Cancer Institute and the Broad Institute have used this platform in conjunction with CRISPR/Cas9 loss-of-function screens to identify key regulatory genes, such as PTPN2, TET2, and PI3Kδ, whose deletion can significantly improve the therapeutic potency and durability of the CAR-T response in B-cell malignancies.

Other names

CD20 CAR-TCD-20 CAR-TCD 20 CAR-Tanti-CD20 CAR-Tanti-CD-20 CAR-Tanti-CD 20 CAR-T